Active — Not RecruitingNot Applicable

Detection of Early Idiopathic Pulmonary Fibrosis

United States450 participantsStarted 2018-04-10

Plain-language summary

The purpose of the study is to determine if miR200 family may serve as a biomarker of IPF.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria for IPF Patients: * Informed consent * Subjects ≥ 40 y.o. * Naive patients with no IPF treatment * IPF diagnosis based on the ATS/ERS/JRS/ALAT criteria Inclusion Criteria for non-IPF ILD Patients: * Informed consent * Subjects ≥ 18 y.o. * ILD diagnosis Exclusion Criteria: * HIV * Hepatitis B * Hepatitis C * Pregnant or lactating women inclusion criteria for controls: informed consent \>18 years old; no lung diseases

What they're measuring

To determine miR200 levels (fold change) in blood samples.

Timeframe: Baseline (one time).

Trial details

NCT IDNCT03457935

SponsorTemple University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-12-31

View on ClinicalTrials.gov More Idiopathic Pulmonary Fibrosis trials